Mastоpathy is a biomarker of hormonal distress. Literature review




mammary gland, hormonal diseases, progesterone, Progestogel


Mastopathy is an extensive heterogeneous group of the mammary glands pathologies, varying in its manifestations and in degree of breast cancer risk. The prevalence of mastopathy in female population is 60–80%, and this pathology has an age-related epidemiological features. On the background of gynecological diseases benign breast diseases occur in 76–97.8% of women. Frequency of mastopathy is reduced with the onset of menopause, while the risk of malignant transformation increases. Breast tissue has a high concentration of cytosolic tissue receptors to steroid compounds, so like other organs of women’s reproductive system it is susceptible to 15 hormones. Estrogen concentration in the breast connective tissue in 2–20 times higher than in blood plasma. Decisive role in the emergence of breast pathology belongs not to the absolute concentrations of hormones in blood plasma, but condition of sex steroids receptors in breast tissue. Mastodynia is a reflection of functional changes and response of breast tissue to hormonal imbalance. Proliferative mastopathy without atypia and with atypia significantly increase the risk of breast cancer. Progesterone deficiency is a key factor in the pathogenesis of dishormonal breast diseases.

For timely prevention, early diagnosis of breast diseases and breast cancer, prognosis and treatment tactics, mammography, MRI and ultrasound of the gland are used, as well as various biological markers (tissue, cellular and molecular) determination, steroid hormone receptors, various growth factors and their receptors are evaluated.

The timely appointment of transdermal gel Progestogel® eliminates mastodynia and other symptoms of mastopathy, and is pathogenetic treatment, which prevents the transition of functional disorders into morphological in mammary glands, reduces mammographic breast density, and thus reduces oncology risk.

Thus, prevention, early diagnosis, timely pathogenetic treatment of dishormonal breast diseases reduces the risk of breast cancer.

Author Biographies

Т. А. Ермоленко, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department No. 2

Т. Л. Прутиян, Odesa National Medical University, Odesa

Postgraduate student, Department of Occupational Pathology and Functional Diagnostics


  1. Kamińska, M., Ciszewski, T., Łopacka-Szatan, K. “Breast cancer risk factors.” Prz Menopauzalny 14.3 (2015):196–202. DOI: 10.5114/pm.2015
  2. Prilepskaya, V.N., Bebeneva, T.N. “Possibilities of mastodynia therapy using micronized progesterone.” Women's health 1 (2014): 120–2.
  3. Kotepui, M., Piwkham, D., Chupeerach, C. “Epidemiology and histopathology of benign breast diseases and breast cancer in southern Thailand.” Eur J Gynaecol Oncol 35.6 (2014): 670–5.
  4. Radzinskiy, V.E. Mammary glands and gynecological diseases. Moscow. Status Praesens (2010).
  5. Pavlova, E.A., Arakelov, S.E., Ordiyants, I.M., et al. “Modern views on benign breast dysplasias and their relationship with gynecological diseases.” Vestnik RUDN. Medicine. Obstetrics and gynecology 5 (2012): 487–93.
  6. Vereskunova, M.I. Endocrine and metabolic mechanisms of the development of hyperplastic processes of the female reproductive system organs in peri- and postmenopausal women. Thesis for PhD degree. Rostov-na-Donu (2011): 180 p.
  7. Tatarchuk, T.F., Yefimenko, O.A. “To the issue of prevention of mammary glands pathology.” Reproductive endocrinology 6.8 (2012): 10–2. DOI: 10.18370/2309-4117.2012.8.10-16
  8. Kiselev, V.I., Sidorova, I.S., Unanyan, A.D., Muizhnek, E.L. Hyperplastic processes of the organs of the female reproductive system: theory and practice. Moscow. Publishing House “Medpraktika-M” (2010): 235 p.
  9. Radzinsky, V.E., Ordiyants, I.M. “Premenstrual syndrome and benign dysplasia of the mammary glands: realities and prospects.” Women's Health 57 (2011): 71–5.
  10. Heldring, N., et al. “Estrogen receptors: how do they signal and what are their targets.” Physiol Rev 87.3 (2007): 905–31. DOI: 10.1152/physrev.00026.2006
  11. Lundström, E., Conner, P., Naessén, S. “Estrone – a partial estradiol antagonist in the normal breast.” Gynecol Endocrinol 31.9 (2015): 747–9. DOI: 10.3109/09513590.2015.1062866
  12. Musina, E.V. Mechanisms of influence and effectiveness of progesterone preparations in case of fibrocystic breast disease in reproductive age. Thesis abstract for PhD degree. Sankt-Petersburg (2011): 24 p.
  13. Wiebe, J.P., Zhang, G.,Welch, I., Cadieux-Pitre, H.A. “Progesterone metabolites regulare indaction, growth, and suppression of estrogen – and progesterone receptor – negative human breast cell tumors.” Brest Cancer Res 15.3 (2013): 38.
  14. Cherenkov, V.G. Petrov, A.B., Tverezovsky, S.A., Strozhenkov, M.M. “From the pathogenesis of breast tumors and gynecological diseases to a practical solution to the problem.” Russian Oncology Journal 5 (2014): 47–51.
  15. Radzinsky, V.E. Mammary glands and gynecological diseases. Moscow. Status Praesens (2017).
  16. Lebedina, A.V., Prilepskaya, V.N. “Mastalgia: clinic, diagnosis, treatment.” Women's Health 3 (2012): 24–8.
  17. Melgar, V., Espinosa, E., Sosa, E. “Current diagnosis and treatment of hyperprolactinemia.” Rev Med Inst Mex Seguro Soc 54.1 (2016): 111–21.
  18. Smetnik, V.P., Butareva, L.B. “The experience of using the herbal medicine “Cyclodinon” (“Agnukaston”) in patients with insufficiency of the corpus luteum function and hyperprolactinemia.” Reproduction problems 5 (2005): 1–4.
  19. Asriyan, Y.B. Features of the effect of hormonal therapy on the state of the mammary glands in patients with menstrual irregularities of the endocrine genesis. Thesis abstract for PhD degree. Moscow (2010): 24 p.
  20. Tatarchuk, T.F., Yefimenko, O.A. “Hormonal and non-hormonal aspects of dishormonal mammary gland diseases.” Women's Health 7 (2012): 34–6.
  21. Radzinsky, V.E., Ordiyants, I.M., Maslennikova, M.N., Pavlova, E.A. “Breast, and gynecological diseases: from a common pathogenetic view to practical solutions. Health options for women with a combination of uterine fibroids and benign breast dysplasia.” Women's health 6 (2016): 104–9.
  22. Kornatskaya, A.G., Dubenko, O.D. “Benign diseases of the mammary glands in the practice of an obstetrician-gynecologist.” Women's health 2 (2012): 9–20.
  23. Bespalov, V.G., Travina, M.L. “Fibrocystic disease and the risk of breast cancer: literature review.” Tumors of the female reproductive system 11.4 (2015): 58–70.
  24. Dyrstad, S.W., et al. “Breast cancer risk associated with benign breast disease: systematic review and meta-analysis.” Breast Cancer Res Treat 149.3 (2015): 569–75. DOI: 10.1007/s10549-014-3254-6
  25. Rozhkova, N.I., Meskikh, E.V., Burdina, L.M., et al. “Medicinal pathogenetic correction of benign breast diseases.” Tumors of the female reproductive system 2 (2008): 48–54.
  26. Brown, N., Burnett, E., Scurr, J. “Is Breast Pain Greater in Active Females Compared to the General Population in the UK?” Breast J 22.2 (2016):194–201. DOI: 10.1111/tbj.12547
  27. Ngô, C., Seror, J., Chabbert-Buffet, N. “Breast pain: Recommendations.” J Gynecol Obstet Biol Reprod (Paris) 44.10 (2015): 938–46. DOI: 10.1016/j.jgyn.2015.09.039
  28. Dekkers, O.M., Ehrenstein, V., Bengtsen, M., et al. “Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature.” Eur J Endocrinol 173.2 (2015): 269–73.
  29. Kosei, N.V. “Correction of hormonal imbalance in patients with diffuse forms of mastopathy – the basis of pathogenetic therapy and oncoprophylaxis.” Reproductive endocrinology 1.39 (2018): 8–14. DOI: 10.18370/2309-4117.2018.39.8-14
  30. Tatarchuk, T.F., Yefimenko, O.A. “Hyperprolactinemia as the cause of benign breast diseases.” Medical aspects of women's health 5.91 (2015).
  31. Lasachko, S.A. “Modern views of the dyshormonal diseases of the breast (review).” Neoplasm 1.16 (2017): 29–35.



How to Cite

Ермоленко, Т. А., & Прутиян, Т. Л. (2020). Mastоpathy is a biomarker of hormonal distress. Literature review. REPRODUCTIVE ENDOCRINOLOGY, (53), 75–80.



Interdisciplinary consilium